Clinical and experimental gastroenterology · 2025
Elevated Expression of CHAF1A in Hepatocellular Carcinoma Progression and Immune Modulation.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Jiajing, Zhang Ting, Liu Qi, Du Qian
Аннотация
PURPOSE: This study aimed to explore the role of CHAF1A in hepatocellular carcinoma (HCC) progression, focusing on its expression, co-expression genes, genomic alterations, promoter methylation, clinical relevance, prognostic value, and immune associations.
METHODS: CHAF1A mRNA expression was analyzed using UALCAN. Co-expression genes and functions were explored via LinkedOmics. Genomic alterations were assessed using cBioPortal. Promoter methylation and clinical correlations were examined using GEO datasets. Prognostic significance was evaluated via Kaplan-Meier analysis. Immune cell infiltration and checkpoint gene associations were investigated.
RESULTS: CHAF1A was significantly upregulated in HCC and involved in cancer-related pathways. Genomic alterations were prominent in T1-stage tumors, often linked to alcohol-related liver disease. Promoter methylation influenced HCC progression and prognosis. CHAF1A expression correlated with clinical characteristics (gender, stage, grade, etc.) and showed diagnostic potential (AUC = 0.795). High CHAF1A expression predicted poor prognosis across various subgroups and was positively associated with immune cell infiltration and checkpoint genes.
CONCLUSION: CHAF1A plays a critical role in HCC progression, with elevated expression linked to poor prognosis and immune modulation. These findings highlight its potential as a therapeutic target for HCC.
METHODS: CHAF1A mRNA expression was analyzed using UALCAN. Co-expression genes and functions were explored via LinkedOmics. Genomic alterations were assessed using cBioPortal. Promoter methylation and clinical correlations were examined using GEO datasets. Prognostic significance was evaluated via Kaplan-Meier analysis. Immune cell infiltration and checkpoint gene associations were investigated.
RESULTS: CHAF1A was significantly upregulated in HCC and involved in cancer-related pathways. Genomic alterations were prominent in T1-stage tumors, often linked to alcohol-related liver disease. Promoter methylation influenced HCC progression and prognosis. CHAF1A expression correlated with clinical characteristics (gender, stage, grade, etc.) and showed diagnostic potential (AUC = 0.795). High CHAF1A expression predicted poor prognosis across various subgroups and was positively associated with immune cell infiltration and checkpoint genes.
CONCLUSION: CHAF1A plays a critical role in HCC progression, with elevated expression linked to poor prognosis and immune modulation. These findings highlight its potential as a therapeutic target for HCC.